Bristol Myers Raises 2026 Forecast After Q2 Blowout, Eliquis Sales Surge 22%
BMY sits 50% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb delivered a massive Q2 beat and raised its full-year outlook, driven by Eliquis and its growth portfolio. Revenue hit $12.97B, crushing the $11.75B consensus, while adjusted EPS of $2.04 nearly doubled the $1.59 estimate. The company lifted 2026 revenue guidance to $49B-$50B from $46B-$47.5B and adjusted EPS to $6.75-$7.00 from $6.05-$6.35. Eliquis stole the show with $4.48B in sales, up 22%, and its full-year growth forecast was hiked to 20-25% from 10-15%. Newer drugs also outperformed: Reblozyl, Camzyos, Breyanzi, and Qvantig all beat estimates by wide margins. The only soft spot was Opdivo, down 3% to $2.49B, but the subcutaneous version Qvantig is gaining traction with $261M in revenue. This is a clear inflection point — the growth portfolio is now offsetting Revlimid's decline, and the raised guidance signals management's confidence in sustained momentum. For Pfizer, which shares Eliquis profits, the strong performance is a tailwind, but the primary story is Bristol's standalone strength. Shares rose 2.5% premarket, and the magnitude of the beat and guidance raise makes this a must-know event for traders.
At the time of this announcement, BMY was trading at $63.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $128.9B. The 52-week trading range was $42.52 to $64.97. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.